Anti-VEGF therapy for glaucoma

Current Opinion in Ophthalmology

Volumn 21, Issue 2, 2010, Pages 112-117

  Horsley, Michael B ^a   Kahook, Malik Y ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Antivascular endothelial growth factor; Bevacizumab; Neovascular glaucoma; Ranibizumab; Trabeculectomy; Wound modulation

Indexed keywords

BEVACIZUMAB; ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FUMAGILLOL CHLOROACETYLCARBAMATE; RANIBIZUMAB; VASCULOTROPIN A;

CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FIBROBLAST; FLUORESCENCE ANGIOGRAPHY; FOOD AND DRUG ADMINISTRATION; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA ISCHEMIA; REVIEW; TRABECULECTOMY; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; GLAUCOMA, NEOVASCULAR; HUMANS; TRABECULECTOMY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 76949086711     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3283360aad     Document Type: Review

References (52)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
2. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-985.
3. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161:851-858.
4. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature 2005; 438:960-966.
5. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359:843-845.
6. Michaelson IC. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans Ophthalmol Soc UK 1948; 68:137-180.
7. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-1487.
8. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118:445-450.
9. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor mRNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994; 112:1476-1482.
10. Wong J, Wang N, Miller JW, et al. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res 1994; 58:439-451.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
12. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
13. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407:242-248.
14. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26:999-1005.
15. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26:279-284.
16. Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 2009; 24:113-121.
17. Kuang TM, Liu CJ, Chou CK, Hsu WM. Clinical experience in the management of neovascular glaucoma. J Chin Med Assoc 2004; 67:131-135.
18. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001; 108:1767-1776.
19. Tripathi RC, Li J, Tripathi BJ, et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998; 105:232-237.
20. Grover S, Gupta S, Sharma R, et al. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol 2009; 93:273-274.
21. Kahook MY, Shuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006; 37:144-146.
22. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26:352-354.
23. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006; 26:354-356.
24. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142:1054-1056.
25. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142:155-158.
26. Grisanti S, Biester S, Peters S, et al. Bartz-Schmidt KU, for the Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142:158-160.
27. Gheith ME, Siam GA, de Barros DS, et al. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007; 23:487-491.
28. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114:855-859.
29. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115:1571-1580; 1580.e1-3
30. Cornish KS, Ramamurthi S, Saidkasimova S, Ramaesh K. Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye 2009; 23:979-981.
31. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003; 48:314-346.
32. Heuer DK, Parrish RK, Gressel MG, et al. 5-Fluorouracil and glaucoma filtering surgery. II. A pilot study. Ophthalmology 1984; 91:384-394.
33. Chen CW, Huang HT, Sheu MM. Enhancement of IOP control effect on trabeculectomy by local application of anticancer drug. Acta Ophthalmol Scand 1986; 25:1487-1491.
34. Greenfield DS, Suñer IJ, MillerMP, et al. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol 1996; 114:943-949.
35. Suñer IJ, Greenfield DS, Miller MP, et al. Hypotony maculopathy after filtering surgery with mitomycin C. Incidence and treatment. Ophthalmology 1997; 104:207-214.
36. Wolner B, Liebmann JM, Sassani JW, et al. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmology 1991; 98:1053-1060.
37. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging 2006; 37:148-150.
38. Grewal DS, Jain R, Kumar H, et al. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology 2008; 115:2141-2145.
39. Guerriero E, Yu JU, Kahook MY, et al. Morphologic evaluation of bevacizumab (Avastin) treated corneal stromal fibroblasts. Invest Ophthalmol Vis Sci 2006; 47: E-Abstract 1642.
40. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007; 26:977-982.
41. Yu JY, Kahook MY, Noecker RJ, et al. The effect of avastin on conjunctival fibroblasts. American Glaucoma Society. San Francisco, California; 2 March 2007.
42. Qin Q, Van Bergen N, Liew D, et al. Anti-VEGF treatment on human Tenons' fibroblasts scarring activity in vitro [E-Abstract 4541]. Invest Ophthalmol Vis Sci 2008.
43. Vasudevan SK. Anti-VEGF anti-fibrosis: a comparison of ranibizumab and bevacizumab in vitro [E-Abstract 466]. Invest Ophthalmol Vis Sci 2009.
44. Welsandt GR, Mietz H, Becker M, et al. Effect of bevacizumab on 3T3 fibroblasts in vitro: possible role in wound healing modulation [E-Abstract 836]. Invest Ophthalmol Vis Sci 2007.
45. Memarzadeh F, Varma R, Lin LT, et al. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 2009.
46. Kapetansky FM, Pappa KS, Krasnow MA, et al. Subconjunctival injection(s) of bevacizumab for failing filtering blebs [E-Abstract 837]. Invest Ophthalmol Vis Sci 2007.
47. Purcell JM, Teng CC, Tello C, et al. Effect of needle bleb revision with ranibizumab as a primary intervention in a failing bleb following trabeculectomy [E-Abstract 4165]. Invest Ophthalmol Vis Sci 2008.
48. Coote MA, Ruddle JB, Qin Q, Crowston JG. Vascular changes after intra-bleb injection of bevacizumab. J Glaucoma 2008; 17:517-518.
49. Jue A. Angiogenesis: trabeculectomy and bevacizumab. Semin Ophthalmol 2009; 24:122-125.
50. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther 2008; 25:438-443.
51. Gupta V, Jha R, Rao A, et al. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol 2009; 19:435-441.
52. Yu JY, Kahook MY, Schuman JS, et al. Bevacizumab binding to human sclera post topical application [E-Abstract 4815]. Invest Ophthalmol Vis Sci 2007.